CXCR2 and NGFR transduced TIL
/ UT MD Anderson Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 25, 2023
NCI-2014-02655: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
(clinicaltrials.gov)
- P1/2 | N=10 | Completed | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Completed | Trial completion date: Jan 2024 ➔ Apr 2023 | Trial primary completion date: Jan 2024 ➔ Apr 2023
Metastases • Trial completion • Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • CXCL8 • CXCR2 • NGFR
December 10, 2021
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
(clinicaltrials.gov)
- P1/2; N=10; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Jan 2021 ➔ Jan 2024; Trial primary completion date: Jan 2021 ➔ Jan 2024
Clinical • Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • CXCL8 • CXCR2 • MRI • NGF • NGFR
1 to 2
Of
2
Go to page
1